NovoCure Ltd (NASDAQ: NVCR) stock closed at $14.50 on 1/18/24 after a major increase of 16.7%. Moreover, exceptionally high trading volume at 417% of normal accompanied the advance. The stock has declined -1.6% during the last week and has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
NVCR's future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
NovoCure has a current Value Trend Rating of F (Lowest Rating). This rating combines highly consistent signals from two proprietary PTR measures of a stock's attractiveness. NovoCure has a very low Power Rating of 12 and a very low Appreciation Score of 10, triggering the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.